采用免疫组织化学技术,研究血小板源性生长因子(PDGF)、碱性成纤维细胞生长因子(bFGF)、表皮生长因子(EGF)和转化生长因子α(TGFα)在肝硬变(n=30)和非肝硬变患者(n=10)胃冠状静脉壁的表达与分布.结果:肝硬变患者的强阳性检出率分别为93%、89%、70%和68%,非肝硬变者均为0.提示肝硬变门静脉高压症时,门静脉系统的血管壁可产生多种生长因子,并以旁分泌和自分泌方式作用于血管本身,引起血管构形改建和功能障碍.为生长因子阻断/拮抗疗法用于防治血管构形改建提供理论基础. Immunohistochemistry was used to study the effects of platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and transforming growth factor α (TGFα) And non-cirrhotic patients (n = 10) .Results: The positive detection rates of cirrhosis patients were 93%, 89%, 70% and 68%, respectively. Non-cirrhosis Who are 0. Prompted cirrhosis portal hypertension, the portal vein system can produce a variety of vascular wall growth factor, and the role of paracrine and autocrine effects on the blood vessels itself, causing vascular remodeling and dysfunction. Factor blockade / antagonism therapy for the prevention and treatment of vascular reconstruction provide a theoretical basis.